U.S. v. Eli Lilly and Co.

Email This

Drugmaker Eli Lilly and Company agrees to pay $1.415 billion for off-label marketing of the company’s Zyprexa drug.

Although Zyprexa was approved for treating schizophrenia and certain types of bipolar disorder, Lilly admitted marketing the drug for other unapproved uses like the treatment of dementia.

You can read the plea agreement below.